Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 14/20 | 0.56 |
| ▸ | MET | P08581 | 4/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL286188 | 0.85 | ALK (0.75) | ALKPDPK1 | |
| SCHEMBL720236 | 0.84 | ALK (0.63) | ALKPDPK1 | |
| SCHEMBL15300164 | 0.84 | ALK (0.56) | ALKPDPK1CCNE1CDK2 | |
| SCHEMBL721232 | 0.84 | ALK (0.64) | ALKPDPK1 | |
| SCHEMBL722118 | 0.84 | ALK (0.77) | ALKPDPK1 | |
| SCHEMBL719245 | 0.84 | ALK (0.76) | ALKPDPK1 | |
| SCHEMBL720305 | 0.82 | ALK (0.62) | ALKPDPK1 | |
| SCHEMBL26175363 | 0.81 | ALK (0.57) | ALKMETPDPK1 | |
| SCHEMBL15300210 | 0.80 | ALK (0.79) | ALKMETPDPK1 | |
| SCHEMBL10104643 | 0.79 | ALK (0.59) | ALKPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427461-B1 | 3-([1,2,3]TRIAZOL-4-YL)-PYRROLO[2,3-B]PYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-10-09 | — | — | EP | claimed |
| US-8541584-B2 | 3-(1,2,3-triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | MERCK PATENT GMBH (DE) | 2013-09-24 | — | — | US | claimed |
| US-20120053178-A1 | 3-(1,2,3-Triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-01 | — | — | US | claimed |
| EP-2427461-B1 | 3-([1,2,3]TRIAZOL-4-YL)-PYRROLO[2,3-B]PYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-10-09 | — | — | EP | disclosed |
| EP-2427461-B1 | 3-([1,2,3]TRIAZOL-4-YL)-PYRROLO[2,3-B]PYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-10-09 | — | — | EP | disclosed |
| US-8541584-B2 | 3-(1,2,3-triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | MERCK PATENT GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8541584-B2 | 3-(1,2,3-triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | MERCK PATENT GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| WO-2013024282-A2 | COMPOUNDS AND THEIR USES | DOMAINEX LIMITED (GB) | 2013-02-21 | — | — | WO | disclosed |
| US-20120053178-A1 | 3-(1,2,3-Triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-01 | — | — | US | disclosed |
| US-20120053178-A1 | 3-(1,2,3-Triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-01 | — | — | US | disclosed |
| WO-2010127754-A1 | 3-([1,2,3]TRIAZOLE-4-YL)-PYRROLO[2,3-B]PYRIDINE DERIVATES | MERCK PATENT GMBH (DE) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053178-A1 | 3-(1,2,3-Triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | PDK1, PDK2, PDK3 | ALK 2215/4885MET 1922/4885PDPK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.